Mirapex ER approved for advanced Parkinson's Disease
MIRAPEX ER (pramipexole dihydrochloride) extended-release tablets from Boehringer-Ingelheim
In the trial, superiority of Mirapex ER over placebo was demonstrated after 18 weeks of treatment, on both primary and key secondary efficacy endpoints. In addition, maintenance of efficacy was shown in patients who completed 33 weeks of treatment. In the study, Mirapex ER demonstrated similar benefits as Mirapex, each versus placebo, in people with advanced PD.
Mirapex ER is already approved for the treatment of the signs and symptoms of early idiopathic Parkinson's disease.
For more information call (800) 542-6257 or visit us.boehringer-ingelheim.com.